Literature DB >> 12783430

Apolipoprotein C-II deficiency presenting as a lipid encephalopathy in infancy.

Callum J Wilson1, Claudio Priore Oliva, Franco Maggi, Alberico L Catapano, Sebastiano Calandra.   

Abstract

An infant presented with massive hyperchylomicronemia and a severe encephalopathy. MRI showed marked lipid deposition throughout the brain. Despite the normalization of the biochemistry, there was little clinical improvement, and at 18 months of age she has severe developmental delay, a strikingly abnormal MRI. Apolipoprotein C-II, the lipoprotein on chylomicrons responsible for the activation of lipoprotein lipase, was not detectable in blood. Analysis of the APO C-II gene revealed a novel homozygous point mutation, 1118C-->A. Subsequently, another sibling has been born with the same homozygous mutation and similar biochemistry but, perhaps because of early treatment, a normal neurological outcome.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12783430     DOI: 10.1002/ana.10598

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  10 in total

1.  Hyperlipidemia resulting in abnormal density and signal intensity of blood in a neonate with lipoprotein lipase deficiency.

Authors:  K Koral; J McMenamy; N Hauser; N Rollins
Journal:  AJNR Am J Neuroradiol       Date:  2009-12-24       Impact factor: 3.825

2.  Familial chylomicronemia syndrome- an uncommon cause of acute pancreatitis with encephalopathy.

Authors:  Sunil Kumar Kota; Siva Krishna Kota; Sruti Jammula; Kirtikumar D Modi
Journal:  Indian J Gastroenterol       Date:  2012-09

3.  Creation of Apolipoprotein C-II (ApoC-II) Mutant Mice and Correction of Their Hypertriglyceridemia with an ApoC-II Mimetic Peptide.

Authors:  Toshihiro Sakurai; Akiko Sakurai; Boris L Vaisman; Marcelo J Amar; Chengyu Liu; Scott M Gordon; Steven K Drake; Milton Pryor; Maureen L Sampson; Ling Yang; Lita A Freeman; Alan T Remaley
Journal:  J Pharmacol Exp Ther       Date:  2015-11-16       Impact factor: 4.030

4.  Two case reports of familial chylomicronemia syndrome.

Authors:  Yan-Hui Chen; Zhong-Ling Ke; Yan-Xia Wang; Yong Wang; Yong-Zhi Zheng
Journal:  Case Rep Pediatr       Date:  2012-01-23

5.  Orthologous proteins of experimental de- and remyelination are differentially regulated in the CSF proteome of multiple sclerosis subtypes.

Authors:  Nellie A Martin; Arkadiusz Nawrocki; Viktor Molnar; Maria L Elkjaer; Eva K Thygesen; Miklos Palkovits; Peter Acs; Tobias Sejbaek; Helle H Nielsen; Zoltan Hegedus; Finn Sellebjerg; Tihamer Molnar; Eudes G V Barbosa; Nicolas Alcaraz; Ferenc Gallyas; Asa F Svenningsen; Jan Baumbach; Hans Lassmann; Martin R Larsen; Zsolt Illes
Journal:  PLoS One       Date:  2018-08-16       Impact factor: 3.240

6.  Severe Familial Hypertriglyceridemia: Successful Treatment With Insulin and a Modified Meal Plan.

Authors:  Ahila Ayyavoo; Palany Raghupathy; Meenal Agarwal; Paul Hofman
Journal:  J Endocr Soc       Date:  2018-11-01

7.  Plasma exchange therapy for familial chylomicronemia syndrome in infant: A case report.

Authors:  Lei Han; Guangfeng Qiang; Lei Yang; Rui Kou; Qiubo Li; Meiyun Xin; Ruihan Liu; Zhengjun Zhang
Journal:  Medicine (Baltimore)       Date:  2022-08-12       Impact factor: 1.817

8.  Cloning and characterization of an apolipoprotein C2 promoter in the mouse central nervous system.

Authors:  Zhaoyang Li; Bing Du; Shengyang Li; Xiangchuan Lv; Shenglai Zhou; Yang Yu; Wei Wang; Zhihong Zheng
Journal:  Neural Regen Res       Date:  2013-01-15       Impact factor: 5.135

9.  A novel APOC2 gene mutation identified in a Chinese patient with severe hypertriglyceridemia and recurrent pancreatitis.

Authors:  Jingjing Jiang; Yuhui Wang; Yan Ling; Abudurexiti Kayoumu; George Liu; Xin Gao
Journal:  Lipids Health Dis       Date:  2016-01-16       Impact factor: 3.876

Review 10.  Lipophagy and Lipolysis Status in Lipid Storage and Lipid Metabolism Diseases.

Authors:  Anna Kloska; Magdalena Węsierska; Marcelina Malinowska; Magdalena Gabig-Cimińska; Joanna Jakóbkiewicz-Banecka
Journal:  Int J Mol Sci       Date:  2020-08-25       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.